dc.contributor.author
Abajian, Marina
dc.contributor.author
Curto-Barredo, Laia
dc.contributor.author
Krause, Karoline
dc.contributor.author
Santamaria, Eva
dc.contributor.author
Izquierdo, Iñaki
dc.contributor.author
Church, Martin K.
dc.contributor.author
Maurer, Marcus
dc.contributor.author
Giménez-Arnau, Ana
dc.date.accessioned
2018-06-08T04:08:03Z
dc.date.available
2016-03-04T12:47:10.065Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/16647
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-20828
dc.description.abstract
Chronic cold urticaria (ColdU) is a rare disease characterized by mast cell-
mediated wheals and angioedema following cold exposure. Second-generation
H1-antihistamines, such as rupatadine, are the recommended first-line therapy.
As of yet, the effects of rupatadine up-dosing on development of ColdU symptom
have only been partially characterized. Two-centre, randomized, double-blind,
3-way crossover, placebo-controlled study in patients with a confirmed ColdU
was designed to assess the effects of up-dosing of rupatadine. A total of 23
patients were randomized to receive placebo, rupatadine 20 mg/day, and
rupatadine 40 mg/day for 1 week. The primary outcome was change in critical
temperature thresholds and critical stimulation time thresholds after
treatment. Secondary endpoints included assessment of safety and tolerability
of rupatadine. Both 20 and 40 mg rupatadine were highly effective in reducing
critical temperature thresholds (p < 0.001) and critical stimulation time
thresholds (p < 0.001). In conclusion, rupatadine 20 and 40 mg significantly
reduced the development of chronic cold urticaria symptom without an increase
in adverse effects.
en
dc.rights.uri
http://www.medicaljournals.se/acta/index.php/Editorial/open-access-from-2011.html
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic
Cold Urticaria
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Acta Derm Venereol. - 96 (2016), 1, S. 56–59
dcterms.bibliographicCitation.doi
10.2340/00015555-2150
dcterms.bibliographicCitation.url
http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2150
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000024083
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000006072
dcterms.accessRights.openaire
open access